Cytoplasmic expression of the JM403 antigen GlcA-GlcNH 3 + on heparan sulfate glycosaminoglycan in mammary carcinomas—a novel proliferative biomarker for breast cancers with high malignancy

Masahiro Fujii(Aichi Cancer Center), Mamoru Kyogashima(Nagoya City University), Koji Oda(Tokyo Metropolitan University), Yoshie Shimoyama(Nagoya University Hospital), Yukihiro Yokoyama(Nagoya University), Nobuyuki Tsunoda(Nagoya University), Tsuyoshi Ishimaru(Seikagaku Corporation (Japan)), Akiko Yusa(Aichi Science & Technology Foundation), Johbu Itoh, Masato Nagino(Nagoya University), Yoshiko Itoh(Tokai University), Reiji Kannagi(Institute of Biomedical Sciences, Academia Sinica), Hiroji Iwata(Aichi Cancer Center), Hirotoshi Utsunomiya(Tokai University), Toshio Kokuryo(Nagoya University)
Glycoconjugate Journal
October 1, 2010
10.1007/s10719-010-9311-4
Cited by 6

Related Papers

Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)
|Surgery|2011|2.3k
Bile leakage after hepatobiliary and pancreatic surgery: A definition and grading of severity by the International Study Group of Liver Surgery
|Surgery|2011|1.9k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k